AUR-200-2024-02: A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis (clinicaltrialsregister.eu) - May 18, 2026 - P1/2 | N=19 | Not yet recruiting | Sponsor: Aurinia Pharmaceuticals Inc.
New P1/2 trial • CNS Disorders • Myasthenia Gravis
|